CRISPR Therapeutics AG (NASDAQ:CRSP) and Adial Pharmaceuticals Inc. (NASDAQ:ADIL), both competing one another are Biotechnology companies. We will compare their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CRISPR Therapeutics AG 60 0.00 34.37M -0.46 0.00
Adial Pharmaceuticals Inc. 2 0.00 6.54M -0.89 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of CRISPR Therapeutics AG and Adial Pharmaceuticals Inc.

Profitability

Table 2 provides the net margins, return on assets and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
CRISPR Therapeutics AG 57,235,636.97% -2.6% -2%
Adial Pharmaceuticals Inc. 419,230,769.23% -89.3% -84.5%

Liquidity

CRISPR Therapeutics AG has a Current Ratio of 8.3 and a Quick Ratio of 8.3. Competitively, Adial Pharmaceuticals Inc.’s Current Ratio is 12.2 and has 12.2 Quick Ratio. Adial Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than CRISPR Therapeutics AG.

Analyst Recommendations

The Ratings and Recommendations for CRISPR Therapeutics AG and Adial Pharmaceuticals Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
CRISPR Therapeutics AG 0 0 3 3.00
Adial Pharmaceuticals Inc. 0 0 0 0.00

CRISPR Therapeutics AG has an average price target of $72, and a 8.45% upside potential.

Institutional & Insider Ownership

Institutional investors owned 46.8% of CRISPR Therapeutics AG shares and 15.2% of Adial Pharmaceuticals Inc. shares. About 0.4% of CRISPR Therapeutics AG’s share are owned by insiders. Insiders Competitively, owned 3.4% of Adial Pharmaceuticals Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
CRISPR Therapeutics AG 1% 49.37% 59.3% 63.07% 101.48% 153.31%
Adial Pharmaceuticals Inc. 4.14% -5.63% -1.31% -25.98% -49.67% -70.51%

For the past year CRISPR Therapeutics AG had bullish trend while Adial Pharmaceuticals Inc. had bearish trend.

Summary

CRISPR Therapeutics AG beats Adial Pharmaceuticals Inc. on 7 of the 10 factors.

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders in the United States. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



Source link